Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 10 2020
Historique:
received: 23 04 2020
accepted: 15 10 2020
entrez: 29 10 2020
pubmed: 30 10 2020
medline: 11 3 2021
Statut: epublish

Résumé

Experimental evidence suggests that ubiquitin-protein ligases regulate a number of cellular processes involved in tumorigenesis. We analysed the role of the E3 ubiquitin-protein ligase HUWE1 for pathobiology of multiple myeloma (MM), a still incurable blood cancer. mRNA expression analysis indicates an increase in HUWE1 expression levels correlated with advanced stages of myeloma. Pharmacologic as well as RNAi-mediated HUWE1 inhibition caused anti-proliferative effects in MM cell lines in vitro and in an MM1.S xenotransplantation mouse model. Cell cycle analysis upon HUWE1 inhibition revealed decreased S phase cell fractions. Analyses of potential HUWE1-dependent molecular functions did not show involvement in MYC-dependent gene regulation. However, HUWE1 depleted MM cells displayed increased DNA tail length by comet assay, as well as changes in the levels of DNA damage response mediators such as pBRCA1, DNA-polymerase β, γH2AX and Mcl-1. Our finding that HUWE1 might thus be involved in endogenous DNA repair is further supported by strongly enhanced apoptotic effects of the DNA-damaging agent melphalan in HUWE1 depleted cells in vitro and in vivo. These data suggest that HUWE1 might contribute to tumour growth by endogenous repair of DNA, and could therefore potentially be exploitable in future treatment developments.

Identifiants

pubmed: 33116152
doi: 10.1038/s41598-020-75499-3
pii: 10.1038/s41598-020-75499-3
pmc: PMC7595222
doi:

Substances chimiques

Antineoplastic Agents, Alkylating 0
Proto-Oncogene Proteins c-myc 0
Tumor Suppressor Proteins 0
HUWE1 protein, human EC 2.3.2.26
Ubiquitin-Protein Ligases EC 2.3.2.27
Melphalan Q41OR9510P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18419

Références

J Biomed Sci. 2018 Sep 4;25(1):67
pubmed: 30176860
Mol Cell Biol. 2005 Apr;25(7):2819-31
pubmed: 15767685
PLoS One. 2016 Nov 28;11(11):e0166956
pubmed: 27893783
Nat Rev Cancer. 2012 Jan 12;12(2):104-20
pubmed: 22237395
Mol Cell. 2017 Oct 5;68(1):233-246.e5
pubmed: 28943312
Mol Cell Biol. 2017 Jan 19;37(3):
pubmed: 27821478
Nat Immunol. 2016 Nov;17(11):1312-1321
pubmed: 27668798
EMBO Mol Med. 2014 Sep 24;6(12):1525-41
pubmed: 25253726
Cell Rep. 2015 Dec 29;13(12):2728-40
pubmed: 26711340
Br J Haematol. 2010 May;149(4):529-36
pubmed: 20331455
Sci Rep. 2016 Jun 06;6:26979
pubmed: 27264969
Oncotarget. 2017 Aug 24;8(49):85858-85867
pubmed: 29156762
J Exp Med. 2012 Jan 16;209(1):173-86
pubmed: 22213803
Blood. 2004 Dec 1;104(12):3712-21
pubmed: 15297310
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Biochem Biophys Res Commun. 2014 Feb 21;444(4):549-54
pubmed: 24472556
EMBO J. 2009 Oct 21;28(20):3207-15
pubmed: 19713937
EMBO Rep. 2016 Jun;17(6):874-86
pubmed: 27146073
PLoS One. 2015 Mar 19;10(3):e0121581
pubmed: 25790254
Oncotarget. 2016 Feb 9;7(6):6521-37
pubmed: 26695547
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70
pubmed: 21307310
Oncogene. 2005 Apr 7;24(15):2461-73
pubmed: 15735737
Leukemia. 2018 Jan;32(1):111-119
pubmed: 28588253
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
J Clin Invest. 2018 Jan 2;128(1):500-516
pubmed: 29227281
Front Oncol. 2017 May 19;7:98
pubmed: 28580318
Expert Rev Proteomics. 2018 Dec;15(12):1033-1052
pubmed: 30427223
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):437-42
pubmed: 22203964
Int J Mol Sci. 2012;13(5):6204-19
pubmed: 22754359
EMBO Mol Med. 2017 Feb;9(2):181-197
pubmed: 28003334
Cell. 2005 Jul 1;121(7):1085-95
pubmed: 15989957
Sci Rep. 2017 Nov 10;7(1):15353
pubmed: 29127375
Leukemia. 2013 Feb;27(2):441-50
pubmed: 22772059

Auteurs

Viktoria Kunz (V)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Kathryn S Bommert (KS)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Jessica Kruk (J)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Daniel Schwinning (D)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Manik Chatterjee (M)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Thorsten Stühmer (T)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Ralf Bargou (R)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany.

Kurt Bommert (K)

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Versbacher Str. 5, 97078, Würzburg, Germany. kurt.bommert@uni-wuerzburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH